Effects of indomethacin on viral replication markers in asymptomatic carriers of hepatitis B: A randomized, placebo-controlled trial

American Journal of Gastroenterology

Volumn 100, Issue 4, 2005, Pages 856-861

  Bahrami, Hossein ^a   Daryani, Nasser E ^b   Haghpanah, Babak ^b   Moayyeri, Alireza ^b   Moghadam, Katayoon Fayaz ^b   Mirmomen, Shahram ^b   Kamangar, Farin ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTACID AGENT; HEPATITIS B SURFACE ANTIGEN; INDOMETACIN; PLACEBO; VIRUS DNA; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DNA DETERMINATION; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG TOLERABILITY; ECHOGRAPHY; FEMALE; FOLLOW UP; GASTRITIS; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEROCONVERSION; SERUM; STATISTICAL ANALYSIS; SYMPTOM; TREATMENT OUTCOME; VIRUS CARRIER; VIRUS REPLICATION; BLOOD; HETEROZYGOTE; IMMUNOLOGY; MIDDLE AGED;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARRIER STATE; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INDOMETHACIN; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 17544376244     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.41144.x     Document Type: Article

References (28)

1. Maynard JE. Hepatitis B: Global importance and need for control. Vaccine 1990;8(Suppl):S18.
2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225-41.
3. Ghavanini AA, Sabri MR. Hepatitis B surface antigen and anti-hepatitis C antibodies among blood donors in the Islamic Republic of Iran. East Mediterr Health J 2000;6:1114-6.
4. Baskin G. Interferon signalling through arachidonic acid-dependent pathways: A clue to adjuvant therapy for chronic viral hepatitis? Hepatology 1991;14:392-4.
5. Hannigan GE, Williams BR. Signal transduction by interferon-alpha through arachidonic acid metabolism. Science 1991;251:204-7.
6. Samuelsson B. Biosynthesis of prostaglandins. Fed Proc 1972;31:1442-50.
7. Fitzpatrick FA, Murphy RC. Cytochrome P-450 metabolism of arachidonic acid: Formation and biological actions of "epoxygenase"-derived eicosanoids. Pharmacol Rev 1988;40:229-41.
8. Brunda MJ, Herberman RB, Holden HT. Inhibition of murine natural killer cell activity by prostaglandins. J Immunol 1980;124:2682-7.
9. Koren HS, Anderson SJ, Fischer DG, et al. Regulation of human natural killing. I. The role of monocytes, interferon, and prostaglandins. J Immunol 1981;127:2007-13.
10. Wolf M, Droege W. Inhibition of cytotoxic responses by prostaglandin E2 in the presence of interleukin 2. Cell Immunol 1982;72:286-93.
11. Andreone P, Cursaro C, Gramenzi A, et al. Indomethacin enhances serum 2′5′-oligoadenylate synthetase in patients with hepatitis B and C virus chronic active hepatitis. J Hepatol 1994;21:984-8.
12. Andreone P, Cursaro C, Gramenzi A, et al. Interferon alpha plus ketoprofen or interferon alpha plus ribavirin in chronic hepatitis C non-responder to interferon alpha alone: Results of a pilot study. Ital J Gastroenterol Hepatol 1999;31:688-94.
13. Munoz AE, Levi D, Podesta A, et al. Interferon-alpha 2b combined with daily ketoprofen administration improves virological response in chronic hepatitis C: A prospective and randomised trial. Gut 2000;46:427-31.
14. Andreone P, Gramenzi A, Cursaro C, et al. Interferon-alpha combined with ketoprofen as treatment of naive patients with chronic hepatitis C: A randomized controlled trial. J Viral Hepat 2003;10:306-9.
15. Giambartolomei S, Artini M, Almerighi C, et al. Non-steroidal anti-inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phosphorylation. Hepatology 1999;30:510-6.
16. Kapicioglu S, Sari M, Kaynar K, et al. The effect of indomethacin on hepatitis B virus replication in chronic healthy carriers. Scand J Gastroenterol 2000;35:957-9.
17. Sadi S, Farrohi K, McCollum RW, et al. Hepatitis-B antigen in Iran: Frequency and subtype. Lancet 1972;2:1377-8.
18. Tabarestani M, Hoofnagle JH, Afkari A. Type B hepatitis in Iran. Acta Med Iran 1977;20:105-10.
19. Andre F. Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine 2000;18(Suppl 1):S20.
20. Zali MR, Mohammad K, Farhad A, et al. Epidemiology of hepatitis B in the Islamic Republic of Iran. East Mediterr Health J 1996;2:290-298
21. Alter HJ, Seeff LB, Kaplan PM, et al. Type B hepatitis: The infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med 1976;295:909-13.
22. Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Hepatology 1988;8:493-6.
23. Yu MW, Hsu FC, Sheen IS, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997;145:1039-47.
24. Schwartz J, Carithers R Jr. Epidemiology and etiologic associations of primary hepatocellular carcinoma. In: UpToDate, Rose, BD, ed. UpToDate. Wellesley, MA, 2004.
25. Nagelkerke N, Fidler V, Bernsen R, et al. Estimating treatment effects in randomized clinical trials in the presence of non-compliance. Stat Med 2000;19:1849-64.
26. Liaw YF, Sheen IS, Chen TJ, et al. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study. Hepatology 1991;13:627-31.
27. Kato Y, Nakao K, Hamasaki K, et al. Spontaneous loss of hepatitis B surface antigen in chronic carriers, based on a long-term follow-up study in Goto Islands, Japan. J Gastroenterol 2000;35:201-5.
28. Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986;6:167-72.